Electronic supplementary materials

ESM Table 1 Effect of adrenaline increase on the acute increase in count of granulocytes, lymphocytes and monocytes during hypoglycemia.

	Effect	p-value
Granulocytes	2.029	0.004
Lymphocytes	1.212	0.001
Monocytes	0.196	0.041

ESM methods

Inclusion criteria - overall

- Ability to provide written informed consent
- Must be able to speak and read Danish (for Hillerød-site) and Dutch (for Nijmegen-site)
- Insulin treatment according to basal-bolus insulin regimen (injections or insulin pump)

 (except for healthy participants)
- BMI: $19-40 \text{ kg/m}^2$
- Age \geq 18 years, \leq 80 years
- Blood pressure: < 140/90 mmHg
- Duration of diabetes > 1 year (except for healthy participants)
- $HbA_{1c} < 100 \text{ mmol/mol} (11.3\%)$

Inclusion criteria – subgroup specific

- T2DM: Insulin treatment for at least 1 year and age \geq 18 years, \leq 80 years
- Healthy volunteers: HbA_{1c} < 42 mmol/mol (6%) and age \geq 18 years, \leq 80 years

Exclusion criteria for participants with diabetes


- Severe medical or psychological conditions interfering with the perception of hypoglycemia other than IAH such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders
- Use of immune-modifying drugs or antibiotics
- Treatment with glucose-modifying (other than insulin, SGLT-2 inhibitors and metformin) agents (e.g. prednisolone)

- Use of anti-depressive drugs
- Pregnancy or breastfeeding or unwillingness to undertake measures for birth control
- Use of statins (e.g. stop statins >2 weeks before performing blood sampling. This can be safely done in the context of primary prevention)
- Any event of cardiovascular disease in the 5 years before screening (e.g. myocardial infarction, stroke, heart failure, symptomatic peripheral arterial disease)
- Auto-inflammatory or auto-immune diseases
- Any infection in the three months before screening
- Previous vaccination in the three months before screening
- Laser coagulation for proliferative retinopathy in the six months before screening
- Proliferative retinopathy
- Diabetic nephropathy as reflected by an albumin-creatinine ratio > 30 mg/gor an estimated glomerular filtration rate (by MDRD) <60ml/min/1.73m²
- History of pancreatitis (acute or chronic) or pancreatic cancer


Exclusion criteria for participants without diabetes


- Presence of any medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders
- Use of any medication, except for oral contraceptives, stable dose of thyroxine
- Pregnancy or breastfeeding or unwillingness to undertake measures for birth control
- Any infection in the three months before screening
- Vaccination in the three months before screening


ESM Figure 1 Determined glucose levels of the hyperinsulinemic-hypoglycemic clamp of participants with type 2 diabetes and healthy controls.




ESM Figure 2 Counts ($\cdot 10^3/\mu L$) of granulocytes (A), lymphocytes (B), and monocytes (C) in participants with type 2 diabetes (black) and controls (grey). Data are presented as the delta \pm SEM, *p < 0.05, **p < 0.01 and ***p < 0.001 change versus euglycemia.









ESM Figure 3 Percentages of monocytes at euglycemia for people with type 2 diabetes (black) and control (grey) and all timepoints characterized by CCR2 (A), CD11b (B), CD36 (C) and CD41 (D). Data presented as mean \pm SEM, *p < 0.05, **p < 0.01 and ***p < 0.01 change versus euglycemia.





ESM Figure 4 Ex vivo cytokine production of TNF- α (A), IL-6 (B), IL-1 β (C) and IL-10 (D) upon LPS or P3C stimulation. Data presented as delta \pm SEM, *p < 0.05, **p < 0.01 and ***p < 0.001 change versus euglycemia.


Manuscript DB22-0246 Reconsider with Major Revision




















ESM Figure 5 Volcano plots of circulating inflammatory proteins among participants with type 2 diabetes and controls during hypoglycemia (A,B), 1 day (C,D), 3 days (E,F) and 7 days (G,H) compared to euglycemia (Wilcoxon paired test FDR<0.0001).

